Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials

Ítems similars

• Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
  per: Lai, Yongchang, et al.
  Publicat: (2018)
• A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
  per: Lisberg, A, et al.
  Publicat: (2018)
• Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC—are we making progress?
  per: Fenchel, Klaus, et al.
  Publicat: (2016)
• Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
  per: Dev, I K, et al.
  Publicat: (2004)
• Anti VEGF-TKI Treatment and New Renal Adverse Events Not Reported in Phase III Trials
  per: Paschke, Luisa, et al.
  Publicat: (2018)